	US 11,806,403 B2
	Therapeutic derivatives of interleukin-22
Kristian Sass-Ørum, Bagsværd (DK); Rasmus Jørgensen, Hellerup (DK); Sebastian Beck Jørgensen, Bagsværd (DK); Henning Thøgersen, Bagsværd (DK); Thomas Hoeg-Jensen, Bagsværd (DK); and Michael Paolo Bastner Sandrini, Bagsværd (DK)
Assigned to CytoKi Pharma ApS, Hellerup (DK)
Filed by CytoKi Pharma ApS, Hellerup (DK)
Filed on May 5, 2022, as Appl. No. 17/737,849.
Application 17/737,849 is a continuation of application No. PCT/EP2020/081523, filed on Nov. 9, 2020.
Claims priority of application No. 19207766 (EP), filed on Nov. 7, 2019.
Prior Publication US 2022/0347304 A1, Nov. 3, 2022
Int. Cl. C07K 14/54 (2006.01); A61K 47/54 (2017.01); A61P 1/16 (2006.01); A61P 3/04 (2006.01); A61P 3/10 (2006.01); A61P 11/00 (2006.01)

CPC A61K 47/542 (2017.08) [A61P 1/16 (2018.01); A61P 3/04 (2018.01); A61P 3/10 (2018.01); A61P 11/00 (2018.01)]

96 Claims

1. A derivative of IL-22 comprising a fatty acid covalently attached to an IL-22 protein by a linker, wherein:

(i) the fatty add comprises C18 diacid;

(ii) the IL-22 protein is a variant of human IL-22 (hIL-22), wherein hIL-22 comprises the amino acid sequence of SEQ ID NO: 1, wherein the variant comprises:

(a) a Cys substitution at position 1 of hIL-22;

(b) an N-terminal G-P-G, and

wherein the fatty acid is covalently attached to the Cys substitution at position 1 of hIL-22 by the linker.